Cingulate (CING) Projected to Announce Quarterly Earnings on Thursday

Cingulate (NASDAQ:CING) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Cingulate to announce earnings of ($0.48) per share and revenue of $0.54 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Cingulate (NASDAQ:CING) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.18. On average, analysts expect Cingulate to post ($2.19) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

Cingulate Stock Down 3.4%

CING opened at $4.56 on Thursday. The company has a fifty day moving average price of $4.97 and a two-hundred day moving average price of $5.43. Cingulate has a 52 week low of $3.16 and a 52 week high of $11.89.

Analyst Ratings Changes

Several research firms have recently issued reports on CING. Roth Capital set a $9.00 price target on Cingulate and gave the stock a “buy” rating in a research report on Sunday, August 23rd. Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 20th. Finally, Wall Street Zen upgraded Cingulate from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

About Cingulate

Cingulate Inc (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient.